抗Feline CCL5/RANTES抗体(Anti-Feline CCL5/RANTES antibody)
掲載日情報：2021/01/28 現在Webページ番号：33364
Feline CCL5/RANTESに対する抗体(Anti-Feline CCL5/RANTES )です。
※ 本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
- 価格
- Product Details
- Applications and Data
- Data Examples
- References
- Related Research Areas
- Related Product & Information
価格
[在庫・価格 ：2025年04月26日 20時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anti-Feline CCL5/RANTES Affinity Purified Polyclonal Ab (100 UG) |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Anti-Feline CCL5/RANTES Affinity Purified Polyclonal Ab |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2025年04月26日 20時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Anti-Feline CCL5/RANTES Affinity Purified Polyclonal Ab (100 UG)
文献数： 0
- 商品コード：AF3819
- メーカー：RSD
- 包装：100μg
- 価格：¥100,000
- 在庫：無(未発注)
- 納期：10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | マッチドペア：Feline CCL5/RANTES サンドイッチELISAの補足用抗体として利用可能，検出用抗体として#BAF3819，スタンダードとして#3819-FR-025を用いる。 別名：chemokine (C-C motif) ligand 5 Genbank No： 6352 Protein Accession No： Q8SQ40 |
||||||
|---|---|---|---|---|---|---|---|
| 別包装品 | 別包装品あり | ||||||
| 法規制等 | |||||||
| 保存条件 | 法規備考 | ||||||
| 抗原種 | Feline | 免疫動物 | Sheep | ||||
| 交差性 | Feline | 適用 | ELISA,Neutralising,Western Blot | ||||
| 標識 | Unlabeled | 性状 | Antigen Affinity Purified | ||||
| 吸収処理 | クラス | IgG | |||||
| クロナリティ | Polyclonal | フォーマット | |||||
| 掲載カタログ |
|
||||||
| 製品記事 | M1/M2 Macrophage Activation Marker |
||||||
| 関連記事 | R&D Systems(R&Dシステムズ)社 ELISA用ペア抗体を使用したELISA 構築ガイド |
||||||
Anti-Feline CCL5/RANTES Affinity Purified Polyclonal Ab
文献数： 0
- 商品コード：AF3819-SP
- メーカー：RSD
- 包装：25μg
- 価格：¥30,000
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | ※受注発注品。形状：溶液または凍結乾燥 別名：chemokine (C-C motif) ligand 5 Genbank No： 6352 Protein Accession No： Q8SQ40 |
||||||
|---|---|---|---|---|---|---|---|
| 別包装品 | 別包装品あり | ||||||
| 法規制等 | |||||||
| 保存条件 | 法規備考 | ||||||
| 抗原種 | 免疫動物 | Sheep | |||||
| 交差性 | Feline | 適用 | ELISA,Neutralising,Western Blot | ||||
| 標識 | Unlabeled | 性状 | Antigen Affinity Purified | ||||
| 吸収処理 | クラス | IgG | |||||
| クロナリティ | Polyclonal | フォーマット | |||||
| 掲載カタログ |
|
||||||
| 製品記事 | M1/M2 Macrophage Activation Marker 使いっきり抗体 |
||||||
| 関連記事 | R&D Systems(R&Dシステムズ)社 ELISA用ペア抗体を使用したELISA 構築ガイド |
||||||
カートに商品を
追加しました。
追加しました。
Product Details
| Species Reactivity | Feline |
|---|---|
| Label | Unconjugated |
| Immunogen | E. coli-derived recombinant feline CCL5/RANTESTyr26-Asn92 (Lys84Tyr and Gly85 del)Accession # Q8SQ40 |
| Source | Polyclonal Sheep IgG |
| Purification | Antigen Affinity-purified |
| Specificity | Detects feline CCL5/RANTES in ELISAs and Western blots. In sandwich immunoassays, less than 0.02% cross-reactivity with recombinant human RANTES, recombinant mouse RANTES, and recombinant cotton rat RANTES is observed. |
カートに商品を
追加しました。
追加しました。
Applications and Data
| Recommended Concentration | Sample | |
| Western Blot | 0.1 µg/mL | Recombinant Feline CCL5/RANTES (Catalog # 3819-FR) |
| Feline CCL5/RANTES Sandwich Immunoassay | Reagent | |
| ELISA Capture (Matched Antibody Pair) | 0.2-0.8 µg/mL | Feline CCL5/RANTES Antibody (Catalog #AF3819 ) |
| ELISA Detection (Matched Antibody Pair) | 0.1-0.4 µg/mL | Feline CCL5/RANTES Biotinylated Antibody (Catalog #BAF3819 ) |
| ELISA Standard | Recombinant Feline CCL5/RANTES Protein (Catalog #3819-FR ) | |
| Neutralization | Measured by its ability to neutralize CCL5/RANTES-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR5. The Neutralization Dose (ND50) is typically 0.5-2.5 µg/mL in the presence of 80 ng/mL Recombinant Feline CCL5/RANTES. | |
| Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website. | ||
カートに商品を
追加しました。
追加しました。
Data Examples
| Neutralization |
 click image to view larger | Chemotaxis Induced by CCL5/RANTES and Neutralization by Feline CCL5/ RANTES Antibody.Recombinant Feline CCL5/ RANTES (Catalog # 3819-FR) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Feline CCL5/ RANTES (80 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Feline CCL5/RANTES Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3819). The ND50 is typically 0.5‑2.5 µg/mL. |
| Reconstitution | Reconstitute at 0.2 mg/mL in sterile PBS. | Reconstitution Buffer Available |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C | |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. | |
| 1 month, 2 to 8 °C under sterile conditions after reconstitution. | ||
| 6 months, -20 to -70 °C under sterile conditions after reconstitution. | ||
| Background: CCL5/RANTES | CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature feline CCL5 shares 84% aa seqeuence identity with canine CCL5 and 71%‑75% with cotton rat, human, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11‑13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14‑16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17). | |
カートに商品を
追加しました。
追加しました。
References
| Schall, T.J. et al. (1990) Nature 347:669. | |
| Bacon, K.B. et al. (1995) Science 269:1727. | |
| Fischer, F.R. et al. (2001) J. Immunol. 167:1637. | |
| Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477. | |
| Kimura, T. et al. (2003) Vet. Dermatol. 14:269. | |
| Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83. | |
| Levy, J.A. (2009) J. Immunol. 182:3945. | |
| Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37. | |
| DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401. | |
| Proost, P. et al. (1998) J. Biol. Chem. 273:7222. | |
| Appay, V. et al. (1999) J. Biol. Chem. 274:27505. | |
| Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885. | |
| von Hundelshausen, P. et al. (2005) Blood 105:924. | |
| von Hundelshausen, P. et al. (2001) Circulation 103:1772. | |
| Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897. | |
| Baltus, T. et al. (2003) Blood 102:1985. | |
| Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271. | |
| Entrez Gene IDs: | 6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline) |
| Alternate Names: | CCL5; chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES |
カートに商品を
追加しました。
追加しました。
Related Research Areas
| Neutralization | |
|---|---|
 | Chemotaxis Induced by CCL5/RANTES and Neutralization by Feline CCL5/RANTES Antibody. Recombinant Feline CCL5/RANTES (Catalog # 3819-FR) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Feline CCL5/RANTES (80 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Feline CCL5/RANTES Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3819). The ND50 is typically 0.5‑2.5 µg/mL. |
カートに商品を
追加しました。
追加しました。
Related Product & Information
| Entrez Gene IDs | 6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline) |
|---|---|
| Background | CCL5/RANTES |
| background_content | Background: CCL5/RANTES CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature feline CCL5 shares 84% aa seqeuence identity with canine CCL5 and 71%‑75% with cotton rat, human, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11‑13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14‑16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17). |
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。